Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Active Psoriatic Arthritis (EQUATOR)
NCT03101670Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of filgotinib in psoriatic arthritis (PsA), sponsored by Galapagos NV. Started Mar 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03101670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101670.